Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma

Haematologica

Volumn 89, Issue 7, 2004, Pages 875-876

  Rothe, Achim ^a   Schulz, Holger ^a   Elter, Thomas ^a   Engert, Andreas ^a   Reiser, Marcel ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Non Hodgkin's lymphoma; Refractory disease; Rituximab

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; RASH; SALVAGE THERAPY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 3242766093     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Hauke RJ, Armitage JO. Treatment of non-Hodgkin lymphoma. Curr Opin Oncol 2000;12:412-8.
2. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982;60:693-7.
3. Ho AD, del Valle F, Ruckle H, Schwammborn J, Schlimok G, Hiddemann W, et al. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. Cancer 1989;64:1388-92.
4. Goss P, Shepherd F, Scott JG, Baker M, Sutton D, Sutcliffe S. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lymphoma 1995;18:123-9.
5. Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 1994;79:508-12.
6. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74.
7. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody DEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66.
8. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32.
9. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 2000;18:332-9.